Evidence map›Paper›PMID 31326613›Full record

ArticleExperimental hematology2019

Expanded potential stem cell media as a tool to study human developmental hematopoiesis in vitro.

Adam C Wilkinson, David J Ryan, Iwo Kucinski, Wei Wang, Jian Yang, Sonia Nestorowa, Evangelia Diamanti, Jason Cheuk-Ho Tsang, Juexuan Wang, Lia S Campos and 5 more

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Experimental hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Adam C WilkinsonDepartment of Haematology, Wellcome & MRC Cambridge Stem Cell Institute, Cambridge, UK.
David J RyanWellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
Iwo KucinskiDepartment of Haematology, Wellcome & MRC Cambridge Stem Cell Institute, Cambridge, UK.
Wei WangWellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
Jian YangWellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
Sonia NestorowaDepartment of Haematology, Wellcome & MRC Cambridge Stem Cell Institute, Cambridge, UK.
Evangelia DiamantiDepartment of Haematology, Wellcome & MRC Cambridge Stem Cell Institute, Cambridge, UK.
Jason Cheuk-Ho TsangWellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
Juexuan WangWellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
Lia S CamposWellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
Fengtang YangWellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
Beiyuan FuWellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
Nicola WilsonDepartment of Haematology, Wellcome & MRC Cambridge Stem Cell Institute, Cambridge, UK.
Pentao LiuWellcome Trust Sanger Institute, Hinxton, Cambridge, UK; School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, Stem Cell and Regenerative Medicine Consortium, University of Hong Kong, Hong Kong, China.
Berthold GottgensDepartment of Haematology, Wellcome & MRC Cambridge Stem Cell Institute, Cambridge, UK. Electronic address: bg200@cam.ac.uk.
Wellcome Sanger Institute · GBWellcome/MRC Cambridge Stem Cell Institute · GBUniversity of Hong Kong · HK

Funding

VISION: ValIdated Systematic IntegratiON of epigenomic dataR24DK106766 · NIDDK · PENNSYLVANIA STATE UNIVERSITY, THE · PI BLOBEL, GERD A, BODINE, DAVID M. · 2016 to 2020
$6.2M
Cancer Research UK 21762Medical Research Council 1509287Medical Research Council MC_PC_12009Medical Research Council MC_PC_17230Medical Research Council MR/S036113/1NIDDK NIH HHS R24 DK106766Wellcome Trust 098051Wellcome Trust 206328/Z/17/Z
6 · The paper itself

Abstract

Pluripotent stem cell (PSC) differentiation in vitro represents a powerful and tractable model to study mammalian development and an unlimited source of cells for regenerative medicine. Within hematology, in vitro PSC hematopoiesis affords novel insights into blood formation and represents an exciting potential approach to generate hematopoietic and immune cell types for transplantation and transfusion. Most studies to date have focused on in vitro hematopoiesis from mouse PSCs and human PSCs. However, differences in mouse and human PSC culture protocols have complicated the translation of discoveries between these systems. We recently developed a novel chemical media formulation, expanded potential stem cell medium (EPSCM), that maintains mouse PSCs in a unique cellular state and extraembryonic differentiation capacity. Herein, we describe how EPSCM can be directly used to stably maintain human PSCs. We further demonstrate that human PSCs maintained in EPSCM can spontaneously form embryoid bodies and undergo in vitro hematopoiesis using a simple differentiation protocol, similar to mouse PSC differentiation. EPSCM-maintained human PSCs generated at least two hematopoietic cell populations, which displayed distinct transcriptional profiles by RNA-sequencing (RNA-seq) analysis. EPSCM also supports gene targeting using homologous recombination, affording generation of an SPI1 (PU.1) reporter PSC line to study and track in vitro hematopoiesis. EPSCM therefore provides a useful tool not only to study pluripotency but also hematopoietic cell specification and developmental-lineage commitment.

Indexed as

AnimalsCell Culture TechniquesCell CycleCell LineageCells, CulturedCellular Reprogramming TechniquesCulture MediaEmbryoid BodiesFibroblastsGenes, ReporterHematopoiesisHuman Embryonic Stem CellsHumansMiceNeural Stem CellsPluripotent Stem CellsCulture Media

Identifiers

PMID31326613
PMCPMC6859476
OpenAlexW2962780376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.